Neutralising antibodies to IFN-β in patients with multiple sclerosis

Expert Opinion on Biological Therapy

Volumn 6, Issue 8, 2006, Pages 773-785

  Bagnato, Francesca ^a   Riva, Marco ^a   Antonelli, Guido ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Interferon ; Multiple sclerosis; Neutralising antibodies

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

DRUG EFFECT; HUMAN; INCIDENCE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; CLINICAL TRIALS; HUMANS; INTERFERON-BETA; INTERFERONS; MULTIPLE SCLEROSIS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33746858609     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.8.773     Document Type: Review

References (101)

1. RUDICK RA, GOODKIN DE: Multiple Sclerosis Therapeutics. Rudick RA, Goodkin DE (Eds), Martin Dunitz Ltd, London, UK (1999).
2. CALABRESI PA, STONE LA, BASH CN, FRANK JA, MCFARLAND HF: Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology (1997) 48:669-674.
3. STONE LA, FRANK JA, ALBERT PS et al.: Characterization of MRI response to treatment with Interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology (1997) 49:862-869.
4. RICHERT ND, OSTUNI JL, BASH CN, LEIST TP, MCFARLAND HF, FRANK JA: Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult. Scler. (2001)7:49-58.
5. BREX PA, MOLYNEUX PD, SMIDDY P et al.: The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology (2001) 57:2185-2190.
6. POZZILLI C, BASTIANELLO S, KOUDRAIVTSEVA T et al.: Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short-term study in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry (1996) 61:251-258.
7. KNOBLER RL, GREENSTEIN JI, JOHNSON KP et al.: Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J. Interferon Cytokine Res. (1993) 13:333-340.
8. NO AUTHORS LISTED: Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomised controlled trial. The IFNB Multiple Sclerosis Group and The University of British Columbia MS/MRI Analysis Group. Neurology (1995) 45:1277-1285.
9. JACOBS LD, COOKFAIR DL, RUDICK RA et al.: Intramuscular Interferon beta la for disease progression in relapsing-remitting multiple sclerosis. Ann. Neurol. (1996) 39:285-294.
10. NO AUTHORSLISTED: Placebo-controlled multicentre randomised trial of Interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study on Interferon Beta-1b in Secondary-Progressive MS. Lancet (1998) 352:1491-1497.
11. JACOBS LD, BECK RW, SIMON JH et al.: Intramuscular Interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. (2000) 343:898-904.
12. COMI G, FILIPPI M, BARKHOF F et al.: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 357:1576-1582.
13. THE PRISMS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology (2001) 56:1628-1236.
14. SECONDARY PROGRESSIVE EFFICACY CLINICAL TRIALS OF RECOMBINANT INTERFERON BETA-1A IN MS (SPECTRIMS) STUDY GROUP: Randomized controlled trial of interferon beta-1a in secondary progressive MS. Neurology (2001) 56:1496-1504.
15. PANITCH H, GOODIN DS, FRANCIS G et al.: Randomized, comparative study of interferon beta-1a treatment regimen in MS: the EVIDENCE Trial. Neurology (2002) 59:1496-1506.
16. DURELLI L, VERDUN E, BARBERO P et al.: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMININ). Lancet (2002) 359:1453-1460.
17. FREEDMAN MS, FRANCIS GS, SANDERS EA et al.: Randomized study of once-weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from OWIMS study. Mult. Scler. (2005) 11:41-45.
18. POHL D, ROSTASY K, GARTNER J, HANEFELD F: Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology (2005) 64:888-890.
19. LI DK, ZHAO GJ, PATY DW: Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology (2001) 56:1505-1513.
20. SIMON JH, LULL J, JACOBS LD et al.: A longitudinal study of T1 hypointense lesions in relapsing MS: MSRCG trial of interferon beta-1a. Neurology (2000) 55:185-192.
21. MOLYNEUX PD, KAPPOS L, POLMAN C et al.: The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain (2000) 123:2256-2263.
22. RUDICK RA, FISHER E, LEE JC, DUDA JT, SIMON J: Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult. Scler. (2000) 6:365-372.
23. JONESCK, RIDDEHOUGH A, LI DKB, ZHAO GJ, PATY DW: MRI cerebral atrophy in relapsing remitting multiple sclerosis: result of the PRISMS trial. Neurology (2001) 56(Suppl. 3):A379.
24. GASPERINI C, PAOLILLO A, GIUGNI E et al.: MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. Mult. Scler. (2002)8:119-123.
25. FRANK JA, RICHERT ND, BASH C et al.: Interferon-beta-1b slows progression of atrophy in RRMS. Neurology (2004) 62:719-725.
26. FILIPPI M, ROVARIS M, INGLESE M et al.: Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of MS: a randomized, double-blinded, placebo controlled trial. Lancet (2004) 364:1489-1486.
27. RIO J, TINTORE M, NOS C et al.: Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J. Neurol (2005) 252:795-800.
28. KAPPOS L, WEINSHENKER B, POZZILLI C et al.: Interferon beta-1b in secondary progressive MS. A combined analysis of the two trials. Neurology (2004) 63:1779-1787.
29. PANITCH H, MILLER A, PATY D et al.: Interferon beta 1b in secondary progressive MS: results from a 3-year controlled study. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Neurology (2004) 63:1788-1795.
30. LEARY SM, MILLER DH, STEVENSONV VL, BREX PA, CHARD DT, THOMPSON AJ: Interferon β-1b in primary-progressive MS: an exploratory, randomized, controlled trial. Neurology (2003) 60:44-51.
31. SYED AR, AGIUS MA: Current approved options for treating patients with multiple sclerosis. Neurology (2004) 63(Suppl. 6):8-14.
32. JARIUS S, HOHLFELD R: Interferon therapy of multiple sclerosis. Synopsis of various dosage forms. Nervenarzt (2004) 75:1226-1230.
33. WHO: WHO Expert Committee on Biological Standardisation. Thirty-fifth Report. WHO technical report series 725. World Health Organization, Geneva, Switzerland (1985).
34. MEAGERT: The Molecular Biology of Cytokines. Meager T (Ed.), John Wiley & Sons, Chichester, UK (1998).
35. GIOVANNONI G, MUNSCHAUER FE III, DEIOSENHAMMER F: Neutralizing antibodies to interferon beta during the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry (2002) 73:465-469.
36. ORTENZI C: Neutralising antibodies to interferon β. J. Neurol. Neurosurg. Psychiatry (2003)74:1162.
37. ANTONELLI G: Development of neutralizing and binding antibody to interferon (IFN) in patients undergoing IFN therapy. Antiviral Res. (1994) 24:12-18.
38. NO AUTHORS LISTED: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis, The University of British Columbia MS/MRI Analysis Group. Neurology (1996) 47:889-894.
39. ABDUL-AHAD AK, GALAZKA AR, REVEL M, BIFFONI M, BORDEN EG: Incidence of antibodies to interferon β-1b in patients treated with recombinant human interferon β-1a from mammalian cells. Cytokines Cell. Mol. Ther. (1997) 3:27-32.
40. KIVISAKK P, ALM GV, TAIN WZ, MATUSEVICIUS D, FREDRIKSON S, LINK H: Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis. Mult. Scler. (1997) 3:184-190.
41. ANTONELLI G, BAGNATO F, POZZILLI C et al.: Development of neutralizing antibodies in patients with multiple sclerosis treated with IFN-β-1a. J. Interferon Cytokine Res. (1998) 18:345-350.
42. POLMAN C, KAPPOS L, WHITE R et al.: Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b. Neurology (2003) 60:37-43.
43. KAPPOS L, CLANET M, SANDBERG-WOLLHEIM M et al.: Neutralizing antibodies and efficacy of interferon-β-1a. A 4-year controlled study. Neurology (2005) 65:40-47.
44. VARTANIAN T, SOLBERG SORENSEN P, RICE G: Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol. (2004) 251(Suppl. 2):25-30.
45. PERINI P, CALABRESE M, BIASI G, GALLO P: The clinical impact of interferon beta antibodies in relapsing-remitting MS. J. Neurol. (2004) 251:305-309.
46. ANTONELLI G, BAGNATO F, DIANZANI F: Considerations on the development of serum antibodies to interferon-beta. New Microbiol. (2005) 28:183-192.
47. PETKAU AJ: Statistical approaches to assessing the effects on neutralizing antibodies. IFNβ-1b in the pivotal trial of relapsing-remitting multiple sclerosis. Neurology (2003) 61(Suppl. 5):35-37.
48. CUTTER G: Statistical issues in neutralizing antibodies. Neurology (2003) 61(Suppl. 5):38-39.
49. GNEISS C, REINDL M, BERGER T et al.: Epitope specificity of neutralizing antibodies against IFN-beta. J. Interferon Cytokine Res. (2004) 24:283-290.
50. BENUTZEN K: Anti-IFN BAb and NAb antibodies. Neurology (2003) 61(Suppl. 5):6-10.
51. BAGNATO F, POZZILLI C: Pharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis. Expert Opin. Investig. Drugs (2003) 12:1153-1163.
52. GILLI F, BERTOLOTTO A, SALA A et al.: Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain (2004) 127:259-268.
53. SANTOS R, WEINSTOCK-GUTTMAN B, TAMANO-BLANCO M et al.: Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J. Neuroimmunol. (2006) (In Press).
54. ZANG YC, YANG D, HONG J, TEJADA-SIMON MV, RIVERA VM, ZHANG JZ: Immunoregulation and blocking antibodies induced by interferon β treatment in MS. Neurology (2000) 55:397-404.
55. PERINI P, WADHWA M, BUTTARELLO M et al.: Effects of IFNβ and anti-INFβ antibodies on NK cells in multiple sclerosis patients. J. Neuroimmunol. (2000) 105:91-95.
56. RUDICK RA, SIMONIAN NA, ALAM JA et al.: Incidence and significance of neutralizing antibodies to interferon β-1a in multiple sclerosis. Neurology (1998) 50:1226-1272.
57. DEISENHAMMER F, REINDI M, HARVEY J, GASSE T, DILTZ E, BERGER T: Bioavailability of interferon β 1b in MS patients with and without neutralizing antibodies. Neurology (1999) 52:1239-1243.
58. PUNGOR E, FILES JG, GABE JD et al.: A novel bioassay for the determination of neutralizing antibodies to IFN-β1b. J. Interferon Cytokine Res. (1998) 18:1025-1030.
59. FERNANDEZ O, MAYORGA C, LUQUE G et al.: Study of binding and neutralizing antibodies to interferon-β in two groups of relapsing-remitting multiple sclerosis patients. J. Neurol. (2001) 248:383-388.
60. ROSENBLUM MG, UNGER BW, GUTTERMAN JU, HERSH EM, DAVID GS, FRINCKE JM: Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res. (1985) 45:2421-2424.
61. GILLI F, SALA F, HOFFMANN F et al.: Anti-interferon-beta neutralizing activity is not mediated by antibodies. [Abstract]. Mult. Scler. (2005) 11(Suppl. 1):S2-S11.
62. SCAGNOLARI C, BELLOMI F, TURRIZIANI O et al.: Neutralizing and binding antibodies to IFN-β: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations. J. Interferon Cytokine Res. (2002) 22:207-213.
63. MAYR M, BEREK K, DEISENHAMMER F: Evolution of interferon-beta binding antibodies in MS patients may predict development of neutralizing antibodies. Eur J. Neurol. (2003) 10:462-464.
64. SCHELLEKENS H: The immunogenicity of biopharmaceuticals. Neurology (2003) 61(Suppl. 5):11-12.
65. CLELAND JL, POWELL MF, SHIRE SJ: The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. (1993) 10:307-377;
66. erratum in Crit. Rev. Ther. Drug Carrier Syst. (1994) 11:60
67. ROSENDAAL FR, NIEUWENHUIS HK, VAN DEN BERG HM et al.: A sudden increase in Factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Haemophilia Study Group. Blood (1993)81:2180-2186.
68. BRAUN A, KWEE L, LABOW MA, ALSENZ J: Protein aggregates seem to play a key role among the parameters influencing the antigenicity of Interferon (IFN-alpha) in normal and transgenic mice. Pharm. Res. (1997) 14:1472-1478.
69. PALLERONI AV, AGLIONE A, LABOW M et al.: Interferon immunogenicity: pre-clinical evaluation of interferon-alpha 2a. J. Interferon Cytokine Res. (1997) 17(Suppl. l):23-27.
70. RIFF JC: Clinical investigation of the immunogenicity of interferon-alpha 2a. J. Interferon Cytokine Res. (1997) 17(Suppl. l):29-33.
71. MEAGER A: Natural autoantibodies to interferons. J. Interferon Cytokine Res. (1997) 17(Suppl. l):51-53.
72. MEAGER A, WADHWA, DILGER P et al.: Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. (2003) 132:128-136. A very well detailed and original work on the incidence of natural NABs to IFN in patients with B cell-mediated disease with and without associated malignancy.
73. BAGNATO F, CLEMENZI A, SCAGNOLARI C et al.: Neutralizing antibodies against endogenous Interferon in myasthenia gravis patients. Eur. Cytokine Netw. (2004) 15:24-29.
74. ANTONELLI G: In vivo development of antibody to interferons: an update to 1996. J. Interferon Cytokine Res. (1997) 17:39-46.
75. VON WUSSOW P, JALSCHIES D, FREUND M, DEICHER H: Humoral response to recombinant interferon alpha 2b: results of comparative assay and clinical perspectives. J. Interferon Res. (1989) 9(Suppl. 1):25-31.
76. BERTOLOTTO A, MALUCCHI S, SALA A et al.: Differential effects of three interferon betas on neutralizing antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J. Neurol Neurosurg. Psychiatry (2002) 73:148-153.
77. SORENSEN PS, DEISENHAMMER F, DUDA P et al.: Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J. Neurol. (2005) 11:817-827.
78. CATANI L, GUGLIOTTA L, ZAULI G et al.: In vitro inhibition of interferon alpha-2a antiproliferative activity by antibodies developed during treatment for essential thrombocythaemia. Haematologica (1992) 77:318-323.
79. PRUMMER O, STREICHAN U, HEIMPEL H, PORZSOLT F: Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies. J. Immunol. Methods (1994) 171:45-53.
80. MIRE-SLUIS AR, PAGE LA, MEAGER A et al.: An anti-cytokine bioactivity assay for interferons-alpha, -beta and -omega. J. Immunol. Methods (1996) 195:55-61.
81. PUNGOR E, FILES JG, GABE JD et al.: A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J. Interferon Cytokine Res. (1998) 18:1025-1030
82. GROSSBERG SE, KAWADE Y: The expression of potency of neutralizing antibodies for interferons and other cytokines. Biotherapy (1997) 10:93-98.
83. GROSSBERG SE, KAWADE Y, KOHASE M, YOKOYAMA H, FINTER N: The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J. Interferon Cytokine Res. (2001) 21:729-742.
84. GROSSBERG SE, KAWADE Y, KOHASE M, KLEIN JP: The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res. (2001) 21:743-755.
85. MEDENICA RD, MUKERJEE S, HUSCHART T, CORBITT W: Interferon inhibitor factor predicting success of plasmapheresis in patients with multiple sclerosis. J. Clin. Apher. (1994) 9:216-221.
86. RADAEVA S, JARUGA B, KIM WH, HELLER T, LIANG TJ, GAO B: Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C. Biochem. J. (2004) 379:199-208.
87. CLANET M, RADUE EW, KAPPOS L et al.: A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 59:1507-1517.
88. KAPPOS L, CLANET M, SANDBERG-WOLLHEIM et al.: Neutralizing antibodies and efficacy of interferon beta-la: a 4-year controlled study. Neurology (2005) 65:40-47.
89. SCHWID SR, THORPE J, SHARIEF M et al.: Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis. The EVIDENCE study. Arch. Neurol. (2005) 62:785-792.
90. KIVISAKK P, ALM GV, FREDRIKSON S, LINK H: Neutralizing and binding anti-interferon-β (IFN-β) antibodies. A comparison between IFN-β-1a and IFN-β-1b treatment in multiple sclerosis. Eur J. Neurol. (2000) 7:27-34.
91. ROSS C, CLEMMESEN KM, SVENSON M et al.: Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann. Neurol. (2000) 48:706-712. A very comprehensive study on a large cohort of patients exploring differences in immunogenicity among various IFN preparations.
92. GNEISS C, REINDL M, LUTTEROTTI A et al.: Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult. Scler. (2004) 10:507-510.
93. SORENSEN PS, KOCH-HENRIKSEN N et al.: Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. The Danish Multiple Sclerosis Study Group. Neurology (2005) 65:33-39.
94. BELLOMI F, SCAGNOLARI C, TOMASSINI V et al.: Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J. Neurol Sci. (2003) 215:3-8.
95. HERNDON RM, RUDICK RA, MUNSCHAUER FE III et al.: Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult. Scler. (2003) 11:409-419.
96. RESKE D, WALSER A, HAUPT WF, PETEREIT HF: Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol. Scand. (2004) 109:66-70.
97. RICE GP, PASZNER B, OGER J, LESAUX J, PATY D, EBERS G: The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b. Neurology (1999) 52:1277-1279.
98. KREMENCHUTZKY M: Long-term evolution of anti-IFNβ antibodies in IFNβ-treated MS patients. The London, Canada, MS Clinic experience. Neurology (2003)61(Suppl. 5):29-39.
99. PETKAU AJ, WHITE RA, EBERS GC et al.: Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult. Scler. (2004) 10:126-138. A detailed longitudinal analysis on the effect of NABs in MS patients.
100. PANITCH H, MILLER A, PATY D et al.: Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology (2004) 63:1788-1795.
101. BAGNATO F, GUPTA S, RICHERT ND et al.: Effects of Interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch. Neurol. (2005)62:1-5.